Oxford, UK - August 2009
InhibOx has undertaken a lead optimization project with Lauras AS, a Norwegian biotechnology company, to help it advance its drug discovery pipeline. Starting from the existing SAR and available structural data, InhibOx used its proprietary virtual screening platform and expertise to derive structural and QSAR models which rationalized the activity of the known leads and identified novel compounds for synthesis. In addition to novelty, these new compounds offer other potential advantages over previously existing leads.
